NR - Avivagen Exhibits at Annual Woofstock Event
Avivagen Exhibits at Annual Woofstock Event
OTTAWA, ONTARIO, June 14, 2012 - Avivagen Inc. (TSX Venture Exchange: VIV), exhibited at Woofstock, North America's largest outdoor festival for dogs, which took place in Toronto on June 9-10, 2012. The annual event attracted over 300,000 pet parents and their dogs.
Jennifer Febel, the company's Marketing & Social Media Associate, was on hand to speak with pet parents about Oximunol(TM) Chewable Tablets, the canine supplement that features Avivagen's patented proprietary OxC-beta technology. Jennifer commented, "It was good to connect face-to-face with so many pet lovers and their fabulous pooches. Many pet parents were eager to tell me how well their dogs are doing on Oximunol(TM) Chewables and it is clear that there is a definite need for a unique supplement like Oximunol in the pet market. People were interested to learn that the OxC-beta in Oximunol(TM) Chewables supports immune health, which in turn can lead to a variety of health benefits for their dogs. Overall it was a very successful weekend and I am already looking forward to Winter Woofstock, which takes place in Toronto in the Fall."
In the coming weeks Avivagen will follow up via email, Facebook and Twitter on the progress of the more than 250 dogs currently sampling Oximunol(TM) Chewables.
About OxC-beta
OxC-beta is Avivagen's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement. Specific benefits include better growth and utilization of feed in food production animals such as poultry and swine.
About Avivagen
Avivagen, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com and www.chemaphor.com.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David HankinsonGraham Burton, PhD
CEO, Avivagen Inc.President and Co-Founder, Avivagen Inc.
Phone: 902-825-9270Phone: 613-990-0969
d.hankinson@avivagen.comg.burton@avivagen.com